Literature DB >> 1827056

Left ventricular midwall mechanics in systemic arterial hypertension. Myocardial function is depressed in pressure-overload hypertrophy.

G Shimizu1, Y Hirota, Y Kita, K Kawamura, T Saito, W H Gaasch.   

Abstract

BACKGROUND: Left ventricular (LV) midwall geometry has been described conventionally as the sum of the chamber radius and half of the wall thickness; this convention is based on the assumption of uniform transmural thickening during systole. However, theoretical considerations and experimental data indicate that the inner half (inner shell) of the LV wall thickens more than the outer half (outer shell). Thus, an end-diastolic circumferential midwall fiber exhibits a relative migration toward the epicardium during systole. As a result, the conventional method provides an overestimate of the extent of the midwall fiber shortening. METHODS AND
RESULTS: We developed an ellipsoidal model with a concentric two-shell geometry (nonuniform thickening) to assess midwall fiber length transients throughout the cardiac cycle. This modified midwall method was used in the analysis of LV cineangiograms from 15 patients with systemic arterial hypertension and 14 normal subjects. Study groups were classified according to LV mass index (LVMI): 14 normal subjects (group I), eight hypertensive patients with a normal LVMI (group II), and seven hypertensive patients with an increased LVMI (group III). There were no significant differences in LV end-diastolic pressure or volume among the three groups; the ejection fraction was slightly greater in group II (70 +/- 5%) than in groups I (65 +/- 8%) and III (66 +/- 4%), but this trend did not achieve statistical significance. Values for endocardial and conventional midwall fractional shortening (FS) were also similar in the three groups. By contrast, FS by the concentric two-shell geometry (modified midwall method) in group III (16 +/- 2%) was significantly less than that seen in groups I and II (21 +/- 4% and 21 +/- 5%, respectively; both p less than 0.05). This difference achieves greater importance when it is recognized that mean systolic circumferential stress was lower in group III (151 +/- 22 g/cm2) than in groups I and II (244 +/- 37 g/cm2 and 213 +/- 38 g/cm2, respectively; both p less than 0.01). The midwall stress-shortening coordinates in six of the seven group III patients were outside the 95% confidence limits for the normal (group I) subjects. Thus, despite a normal ejection fraction, systolic function is subnormal in hypertensive patients with LV hypertrophy.
CONCLUSIONS: Chamber dynamics provide an overestimate of myocardial function, especially when LV wall thickness is increased. This is due to a relatively greater contribution of inner shell thickening in pressure-overload hypertrophy.

Entities:  

Mesh:

Year:  1991        PMID: 1827056     DOI: 10.1161/01.cir.83.5.1676

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  44 in total

Review 1.  The role of echocardiographic deformation imaging in hypertrophic myopathies.

Authors:  Maja Cikes; George R Sutherland; Lisa J Anderson; Bart H Bijnens
Journal:  Nat Rev Cardiol       Date:  2010-05-11       Impact factor: 32.419

2.  Peak exercise oxygen uptake and left ventricular systolic and diastolic function and arterial mechanics in healthy young men.

Authors:  Vittorio Palmieri; Emiliano Antonio Palmieri; Emma Arezzi; Pasquale Innelli; Maria Sabatella; Liberato Aldo Ferrara; Serafino Fazio; Aldo Celentano
Journal:  Eur J Appl Physiol       Date:  2003-12-03       Impact factor: 3.078

Review 3.  Increased prevalence of concentric left ventricular hypertrophy in African-Americans: will an epidemic of heart failure follow?

Authors:  Sandeep Kamath; David Markham; Mark H Drazner
Journal:  Heart Fail Rev       Date:  2006-12       Impact factor: 4.214

4.  Telomere length and adrenergic-induced left ventricular dilatation and systolic chamber dysfunction in rats.

Authors:  Andrew R Raymond; Bryan Hodson; Angela J Woodiwiss; Gavin R Norton; Richard L Brooksbank
Journal:  Eur J Appl Physiol       Date:  2013-09-06       Impact factor: 3.078

5.  Impact of prehypertension on left ventricular structure, function and geometry.

Authors:  Jugal Kishore Bajpai; Sahay A P; Agarwal A K; De A K; Bindu Garg; Ashish Goel
Journal:  J Clin Diagn Res       Date:  2014-04-15

6.  Cardiac remodeling in patients with primary aldosteronism.

Authors:  F Galetta; G Bernini; F Franzoni; A Bacca; I Fivizzani; L Tocchini; M Bernini; P Fallahi; A Antonelli; G Santoro
Journal:  J Endocrinol Invest       Date:  2009-10       Impact factor: 4.256

7.  Adducin 1 (alpha) Gly460Trp variant is associated with left ventricular geometry in Caucasians and African Americans: The HyperGEN Study.

Authors:  Krati Chauhan; Richard B Devereux; Dc Rao; Ulrich Broeckel; Charles C Gu; Paul Hopkins; Donna K Arnett
Journal:  Int J Mol Epidemiol Genet       Date:  2010-02-26

8.  Higher plasma leptin levels are associated with reduced left ventricular mass and left ventricular diastolic stiffness in black women: insights from the Genetic Epidemiology Network of Arteriopathy (GENOA) study.

Authors:  Daisuke Kamimura; Takeki Suzuki; Wanmei Wang; Matthew deShazo; John E Hall; Michael D Winniford; Iftikhar J Kullo; Thomas H Mosley; Kenneth R Butler; Michael E Hall
Journal:  Hypertens Res       Date:  2018-06-15       Impact factor: 3.872

9.  Inappropriate left ventricular mass in children and young adults with chronic renal insufficiency.

Authors:  Francesca Raimondi; Marcello Chinali; Daniela Girfoglio; Margherita Benincasa; Luciano Pasquini; Francesco Emma; Giovanni de Simone; Maria Chiara Matteucci
Journal:  Pediatr Nephrol       Date:  2009-05-15       Impact factor: 3.714

10.  Normal ranges and physiological changes of midwall fractional shortening in healthy korean population.

Authors:  Kyungil Park; Sung-A Chang; Hyung-Kwan Kim; Hyo-Eun Park; Sang-Hoon Na; Yong-Jin Kim; Dae-Won Sohn; Byung-Hee Oh; Young-Bae Park
Journal:  Korean Circ J       Date:  2010-11-30       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.